FLT3 Mutation Analysis, Bone Marrow

Last Modified: 3/9/2021 10:29:09 AM

Specimen Requirements: 5.0 mL Whole Blood in a Lavender Top Tube - EDTA
Minimum Volume: 0.3 mL Whold Blood
Transport & Storage: Temperature/Stability: 14 days Ambient
14 days Refrigerated
Rejection Criteria: Clotted • Gross hemolysis
Reference Range:

FLT3 ITD:            Not detected
FLT3 TKD:           Not detected 

Methodology: Polymerase Chain Reaction (PCR)
Clinical Significance: FLT3 (fms-like tyrosine kinase-3) is a receptor tyrosine kinase that plays a significant role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations of FLT3 represent one of the most frequent molecular mutations in acute myeloid leukemia (AML) and are reported in 25-30% of the patients. These mutations predominantly include FLT3 internal tandem duplications (ITD) which occur in the region of the gene encoding the juxtamembrane region of the protein and point mutations in the tyrosine kinase domain (TKD). The TKD mutations most frequently involve mutation or deletion of codons D835 or I836. Both ITD and TKD mutations constitutively activate FLT3 kinase activity without the need for the ligand and hence promote malignancy. AML patients with FLT3 internal tandem duplication (ITD) mutations have poor prognosis, high relapse rates, and reduced overall survival. Patients with FLT3 mutations could be eligible for FLT3-targeted therapy regimens.
Custom Panel: No


Turn Around Time: 3 to 5 days
Days Performed: Sunday, Monday, Tuesday, Wednesday, Thursday, Friday, Saturday
Sites Performed: Quest - Chantilly
PHL Test Code: MFLT3
Send Out Test Code: 39786
Alternate Test Names: Acute Myeloid Leukemia; AML; fms-like tyrosine kinase 3; ITD; TKD
CPT Coding: 81245, 81246

Go back to the top of the page.